A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer

Trial Profile

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs UV 1 (Primary) ; Sargramostim
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ultimovacs AS
  • Most Recent Events

    • 04 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2020.
    • 05 Apr 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
    • 05 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top